Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation

American Journal of Transplantation

Volumn 7, Issue 7, 2007, Pages 1763-1769

  Bodingbauer, M ^a   Wekerle, T ^a   Pakrah, B ^b   Roschger, P ^c   Peck Radosavljevic, M ^a   Silberhumer, G ^a   Grampp, S ^a   Rockenschaub, S ^a   Berlakovich, G ^a   Steininger, R ^a   Klaushofer, K ^c   Oberbauer, R ^a   Muhlbacher F ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Bone complications; Liver transplantation; Quality of life

Indexed keywords

BIOCHEMICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM CARBONATE; COLECALCIFEROL; OSTEOCALCIN; ZOLEDRONIC ACID;

ADULT; ARTHRALGIA; ARTICLE; BIOCHEMISTRY; BONE DENSITOMETRY; BONE DENSITY; BONE METABOLISM; BONE TURNOVER; BRAIN HEMORRHAGE; CENTRAL PONTINE MYELINOLYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; DRUG INFUSION; DRUG WITHDRAWAL; FEMALE; FEMUR NECK; FEVER; FOLLOW UP; FRACTURE; GRAFT VERSUS HOST REACTION; HEART ARREST; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPOCALCEMIA; INCIDENCE; INFECTION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LIVER THROMBOSIS; LIVER TRANSPLANTATION; LOG RANK TEST; LYMPHOPROLIFERATIVE DISEASE; MALE; MORPHOMETRICS; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; OPEN STUDY; PARAMETER; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPTICEMIA; SIDE EFFECT; STATISTICAL MODEL; THROMBOSIS; TRABECULAR BONE;

BIOLOGICAL MARKERS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; IMIDAZOLES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 34250223414     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2007.01844.x     Document Type: Article

References (31)

1. Carey EJ, Balan V, Kremers WK, Hay JE. Osteopenia and osteoporosis in patients with end-stage liver disease caused by hepatitis C and alcoholic liver disease: Not just a cholestatic problem. Liver Transpl 2003 9 : 1166 1173.
2. Abbott KC, Oglesby RJ, Hypolite IO et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol 2001 11 : 450 457.
3. Compston JE. Osteoporosis after liver transplantation. Liver Transpl 2003 9 : 321 330.
4. Rouillard S, Lane NE. Hepatic osteodystrophy. Hepatology 2001 33 : 301 307.
5. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol 2000 12 : 931 935.
6. Navasa M, Monegal A, Guanabens N et al. Bone fractures in liver transplant patients. Br J Rheumatol 1994 33 : 52 55.
7. Reeves HL, Francis RM, Manas DM, Hudson M, Day CP. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation. Liver Transpl Surg 1998 4 : 404 409.
8. Ninkovic M, Love S, Tom BD, Bearcroft PW, Alexander GJ, Compston JE. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation. J Hepatol 2002 37 : 93 100.
9. Vedi S, Ninkovic M, Garrahan NJ, Alexander GJ, Compston JE. Effects of a single infusion of pamidronate prior to liver transplantation: A bone histomorphometric study. Transpl Int 2002 15 : 290 295.
10. Coco M, Glicklich D, Faugere MC et al. Prevention of bone loss in renal transplant recipients: A prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol 2003 14 : 2669 2676.
11. Krieg MA, Seydoux C, Sandini L et al. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: A prospective study. Osteoporos Int 2001 12 : 112 116.
12. Cahill BC, O'Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: A pilot study. Transplantation 2001 72 : 1251 1255.
13. Millonig G, Graziadei IW, Eichler D et al. Alendronate in combination with calcium and vitamin D prevents bone loss after orthotopic liver transplantation: A prospective single-center study. Liver Transpl 2005 11 : 960 966.
14. Hardinger KL, Ho B, Schnitzler MA et al. Serial measurements of bone density at the lumbar spine do not predict fracture risk after liver transplantation. Liver Transpl 2003 9 : 857 862.
15. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 346 : 653 661.
16. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001 91 : 1191 1200.
17. Cheer SM, Noble S. Zoledronic acid. Drugs 2001 61 : 799 805 discussion 806.
18. Fleisch H. Zoledronic acid : An evolving role in the treatment of cancer patients with bone disease. Semin Oncol 2001 28 (2 Suppl 6 45 47.
19. Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med 2005 353 : 898 908.
20. Parfitt AM, Drezner MK, Glorieux FH et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 1987 2 : 595 610.
21. Genant HK, Jergas M, Palermo L et al. Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res 1996 11 : 984 996.
22. Bordier P, Matrajt H, Miravet L, Hioco D. [Histological Measure of the Volume and Resorption of Bone Joints.]. Pathol Biol (Paris) 1964 12 : 1238 1243.
23. Roschger P, Fratzl P, Eschberger J, Klaushofer K. Validation of quantitative backscattered electron imaging for the measurement of mineral density distribution in human bone biopsies. Bone 1998 23 : 319 326.
24. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003 124 : 91 96.
25. Shane E, Rodino MA, McMahon DJ et al. Prevention of bone loss after heart transplantation with antiresorptive therapy: A pilot study. J Heart Lung Transplant 1998 17 : 1089 1096.
26. Bianda T, Linka A, Junga G et al. Prevention of osteoporosis in heart transplant recipients: A comparison of calcitriol with calcitonin and pamidronate. Calcif Tissue Int 2000 67 : 116 121.
27. Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation1. Kidney Int 2000 57 : 684 690.
28. Shane E, Addesso V, Namerow PB et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med 2004 350 : 767 776.
29. Crawford BA, Kam C, Pavlovic J et al. Zoledronic acid prevents bone loss after liver transplantation: A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2006 144 : 239 248.
30. Watts NB, Geusens P, Barton IP, Felsenberg D. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res 2005 20 : 2097 2104.
31. Haas M, Leko-Mohr Z, Roschger P et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int 2003 63 : 1130 1136.